Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14951121 | 0.89 | NOD1 (0.32) | NOD1 | |
| SCHEMBL22919489 | 0.87 | KISS1R (0.35) | KISS1RNOD1 | |
| SCHEMBL20227446 | 0.85 | NOD1 (0.40) | NOD1 | |
| SCHEMBL20032178 | 0.85 | NOD1 (0.40) | NOD1 | |
| SCHEMBL14393113 | 0.84 | NOD1 (0.33) | KISS1RNOD1 | |
| SCHEMBL14614152 | 0.84 | NOD1 (0.31) | NOD1 | |
| SCHEMBL15304756 | 0.84 | KISS1R (0.32) | KISS1RNOD1 | |
| SCHEMBL23743653 | 0.81 | KISS1R (0.36) | KISS1R | |
| SCHEMBL13366903 | 0.80 | KISS1R (0.53) | KISS1R | |
| SCHEMBL14525182 | 0.80 | KISS1R (0.53) | KISS1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3532486-B1 | ANTIBODY-COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-09-22 | — | — | EP | disclosed |
| WO-2018081367-A1 | CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-03 | — | — | WO | disclosed |
| EP-2598648-B1 | N-GLYCOSYLATION IN TRANSFORMED PHAEODACTYLUM TRICORNUTUM | Université de Rouen (FR) | 2017-11-08 | — | — | EP | disclosed |
| US-20170304383-A1 | SMALL MOLECULE RAS INHIBITORS | OHIO STATE INNOVATION FOUNDATION | 2017-10-26 | — | — | US | disclosed |
| WO-2017117411-A1 | ANALOGUES OF HEPCIDIN MIMETICS WITH IMPROVED IN VIVO HALF LIVES | PROTAGONIST THERAPEUTICS, INC. (US) | 2017-07-06 | — | — | WO | disclosed |
| WO-2015188934-A1 | CONJUGATE COMPRISING A NEUROTENSIN RECEPTOR LIGAND AND USE THEREOF | 3B PHARMACEUTICALS GMBH (DE) | 2015-12-17 | — | — | WO | disclosed |
| EP-1984384-B1 | Conotoxin analogues, and methods for synthesis of intramolecular dicarba bridge containing peptides | SYNGENE LTD (AU) | 2015-10-21 | — | — | EP | disclosed |
| US-20150093787-A1 | COMPOSITIONS AND METHODS FOR USE IN RECOMBINATIONAL CLONING OF NUCLEIC ACIDS | LIFE TECHNOLOGIES CORP (US) | 2015-04-02 | — | — | US | disclosed |
| US-8924597-B2 | Domain management processor | HEWLETT-PACKARD DEVELOPMENT COMPANY, L.P. (US) | 2014-12-30 | — | — | US | disclosed |
| US-8883988-B2 | Compositions for use in recombinational cloning of nucleic acids | Life Technologies Corporation (US) | 2014-11-11 | — | — | US | disclosed |
| US-20080090768-A1 | RECOMBINANT BONE MORPHOGENETIC PROTEIN HETERODIMERS, COMPOSITIONS AND METHODS OF USE | GENETICS INSTITUTE, INC. | 2008-04-17 | — | — | US | disclosed |
| US-20080070842-A1 | RECOMBINANT BONE MORPHOGENETIC PROTEIN HETERODIMERS, COMPOSITIONS AND METHODS OF USE | GENETICS INSTITUTE, INC. | 2008-03-20 | — | — | US | disclosed |
| EP-1857466-A2 | Soluble interleukin-20 receptor | ZymoGenetics, Inc. (US) | 2007-11-21 | — | — | EP | disclosed |
| EP-1585752-B1 | POLYENE POLYKETIDES, PROCESSES FOR THEIR PRODUCTION AND THEIR USE AS A PHARMACEUTICAL | THALLION PHARMACEUTICALS INC (CA) | 2007-11-21 | — | — | EP | disclosed |
| US-20070253971-A1 | Immunogenic composition of vector; diagnostic immunoassays, probes and primers; host cells, genetic vaccines; administering to pregnant pigs | WYETH | 2007-11-01 | — | — | US | disclosed |
| US-20070184513-A1 | Substrates for beta-lactamase and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-08-09 | — | — | US | disclosed |
| US-7244613-B2 | Expression vector comprising nucleotide sequences coding tubercular complex for use in developing vaccines for treatment and prevention of respiratory system disorders; bactericides | INSTITUT PASTEUR (FR) | 2007-07-17 | — | — | US | disclosed |
| EP-1775590-A1 | Non-invasive in vitro method to detect transitional cell carcinoma of the bladder | LABORATORIOS S.A.L.V.A.T., S.A. (ES) | 2007-04-18 | — | — | EP | disclosed |
| US-7184893-B2 | Method for selecting an optimally diverse library of small molecules based on validated molecular structural descriptors | TRIPOS, INC. (US) | 2007-02-27 | — | — | US | disclosed |
| US-20070031864-A1 | Polyvalent cation-sensing receptor in atlantic salmon | HARRIS H W JR | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170304383-A1 | SMALL MOLECULE RAS INHIBITORS | KRAS, NRAS, HRAS | KISS1R 4791/4885NOD1 4320/4885 |
| US-20070184513-A1 | Substrates for beta-lactamase and uses thereof | CMBL, DBH, NCEH1 | KISS1R 3554/4885NOD1 3633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.